AKBA Q4 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M-4.3% YoY

Gross Profit

$58M105.6% margin

Operating Income

-$6M-11.5% margin

Net Income

-$8M-13.7% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$356M

Total Liabilities

$351M

Stockholders' Equity

$5M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$58M	-4.3%
Gross Profit	$58M	$26M	+124.5%
Operating Income	-$6M	-$65M	+90.3%
Net Income	-$8M	-$70M	+89.2%

Revenue Segments

Product

$50M90%

License Collaboration And Other Revenue

$6M10%